March 19, 2008 - Xoft Inc. received expanded clearance from the FDA for the Axxent Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally shielded clinical settings.
Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated.